Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Capital Employed (ROCE) | 8.4% | 25.7% | 17.1% | 2.5% | (9.3%) | 3.5% | 14.2% | 20.4% | 20.7% | 13.2% | 25.4% | 19.6% | 38.3% | 20.9% | 22.9% | (3.9%) | 12.1% | 9.6% | 14.3% | 14.8% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Capital Employed (ROCE) is 15.7%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Capital Employed (ROCE) for United Therapeutics Corporation have been 12.3% over the past three years, and 11.4% over the past five years.
As of today, United Therapeutics Corporation's Return on Capital Employed (ROCE) is 15.7%, which is higher than industry median of (50.6%). It indicates that United Therapeutics Corporation's Return on Capital Employed (ROCE) is Good.